Eterna Therapeutics Faces Nasdaq Delisting, Board Changes

TL;DR

Nasdaq's kicking Eterna out, new bosses in. Big changes ahead.

AI Summary

Eterna Therapeutics Inc. announced on January 3, 2025, that it received a notice from the Nasdaq Stock Market indicating a failure to meet continued listing requirements. The company is also reporting changes in its board of directors and executive officers, including the election of new directors and the appointment of certain officers, alongside details on compensatory arrangements.

Why It Matters

The company's potential delisting from Nasdaq could significantly impact its stock liquidity and investor confidence, while changes in leadership may signal a strategic shift.

Risk Assessment

Risk Level: high — The company has received a notice of delisting from the Nasdaq Stock Market, indicating a significant risk to its continued trading on a major exchange.

Key Players & Entities

• Eterna Therapeutics Inc. (company) — Registrant
• Nasdaq Stock Market (company) — Listing Exchange
• January 3, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.005 — ch registered Common Stock, par value $0.005 per share ERNA The Nasdaq Stock Mar
• $35 million — ities ("MVLS") was below the minimum of $35 million required for continued listing on the N

Filing Documents

• form8-k.htm (8-K) — 39KB
• 0001493152-25-001704.txt ( ) — 212KB
• erna-20250103.xsd (EX-101.SCH) — 3KB
• erna-20250103_lab.xml (EX-101.LAB) — 33KB
• erna-20250103_pre.xml (EX-101.PRE) — 24KB
• form8-k_htm.xml (XML) — 4KB

01 Notice

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 6, 2025, Eterna Therapeutics Inc. (the "Company") received a notice (the "Notice") from the Listing Qualifications Staff ("Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that for the last 35 consecutive business days, the Company's Market Value of Listed Securities ("MVLS") was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the "Market Value Standard"). Nasdaq Listing Rule 5810(c)(3)(C) provides a compliance period of 180 calendar days, or until July 7, 2025, in which to regain compliance with the Market Value Standard. If at any time during the compliance period the Company's MVLS closes at $35 million or more for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance. In the event the Company does not regain compliance with the Market Value Standard by July 7, 2025, the Staff will provide the Company notice that the Company's securities will be subject to delisting, at which time, the Company may appeal the delisting determination. The Notice has no immediate effect on the Company's Nasdaq listing, and its common stock will continue to be listed under the symbol "ERNA."

02 Departure

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Director On January 3, 2025, Dorothy Clarke submitted her resignation from the Board of Directors (the " Board ") of the Company, effective at 11:59 p.m. Eastern Time on January 6, 2025. Ms. Clarke's resignation was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices, and Ms. Clarke continues to serve as the Company's general counsel. Appointment of Director On January 6, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Dr. Elena Ratner to the Board effective January 7, 2025. Dr. Ratner will serve as a member of the Board until the Company's 2025 Annual Meeting of Stockholders and until her successor is duly elected or appointed and qualified or her earlier death, resignation or removal. The Board determined that Dr Ratner is as an "independent director" under applicable rules of the Nasdaq Stock Market. Dr. Ratner will not serve on any committees of the Board at this time. There are no arrangements or understandings between Dr. Ratner and any other person pursuant to which Dr. Ratner was appointed as a member of the Board. The Company has not engaged in any transaction, and there is no currently proposed transaction, in which Dr. Ratner had or will have a direct or indirect material interest that would require disclosure pursuant to Item 404(a) of Regulation S-K. Dr. Ratner will participate in the standard non-employee director compensation arrangements with respect to annual Board member compensation and Board committee member retainers described under the heading "Director Compensation" in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on October 7, 2024. The Company also expects to enter into its s

View Full Filing

View this 8-K filing on SEC EDGAR